[grow_thumb image=”http://telecareaware.com/wp-content/uploads/2015/04/Scanadu-Scout.jpg” thumb_width=”150″ /]UPDATED December has been a mense horribilis for Scanadu, what with bricking the Scanadu Scout next year, missing the Qualcomm XPRIZE finals and a low equity raise.
Scanadu Scout heading to Doorstop and Paperweight-ville. This all-in-one diagnostic device, which promoted itself as a tricorder worthy of Star Trek‘s Bones, announced on 13 December that on 15 May next year, it will deactivate all units. (What Bones would say: “It’s dead, Jim!”) Users of this admittedly investigational device who purchased it for $200 starting in 2014, glitches and all, [TTA 5 Apr 14], are facing not only that it will ‘cease to function’ but also presumably the loss of access to their data as well. A Scanadu spokesperson to TechCrunch last week (13 Dec) attributed the action as necessary to comply with FDA regulations requiring investigational use devices to be deactivated at the end of the study.
Scanadu also failed to make the Qualcomm Tricorder XPRIZE Final Two, also announced on the same day. They had already teamed with Intelesens of Northern Ireland. (More below)
Mobihealthnews reported on Sunday 18 December that Scanadu completed an additional $6.5 million equity funding, according to a SEC filing. Investors are not disclosed. The funding dated 7 December is considerably less than their $35 million Series B raise, primarily from Chinese VC investors, back in April 2015 which is the bulk of their now $56.1 million funding to date (CrunchBase). It is hard to interpret this one way or another, but MHN’s Jonah Comstock doesn’t hesitate to relate it to both the Scout bricking and the XPRIZE loss. To this Editor, it’s either conservative or like a line of credit, but why now, and not what you expect after a healthy Series B.
Returning to the soon-to-be bricked Scouts, there is no mention of current customer compensation, swap or discounting on future purchases of other Scanadu products, such as Vitals, the successor to the Scout, or Urine for urine testing. (more…)
[grow_thumb image=”http://telecareaware.com/wp-content/uploads/2016/11/Mom_using_on_child_ear.jpg” thumb_width=”150″ /]Only a few years ago, the Star of the Future of Digital Health was the ‘tricorder’–that all-in-one vital signs device that Bones on Star Trek
wielded with such élan (when he wasn’t uttering ‘He’s dead, Jim’). We haven’t heard much from Scanadu
since early last year when it raised $35 million for its Series B
and when it teamed with with Northern Ireland’s Intelesens
as a finalist for the seemingly never-ending Qualcomm Tricorder XPRIZE.
(Seven finalists are now in consumer testing with awards in early 2017.)
In the meantime, others have been proceeding in bringing their devices into reality far sooner, for real people with everyday health problems who want to examine a child, another family member or even themselves at home. One of these companies is Israel’s Tyto Care (picture above at left), which received FDA 510(k) Class II clearance for its digital stethoscope snap-on to the main device to monitor heart and lung sounds. The device also includes a digital imaging otoscope for ear exams, a throat scope, a skin camera and thermometer swipe. The Tyto home device includes video guidance instructions as part of the smartphone or tablet platform to enable a correct reading. It connects to an online platform to send the information, either in real time or store-and-forward, to a primary care physician the user selects. Tyto Care has been in investigational marketing in the US as well as Israel, bolstered by over $18 million in international investment. They are targeting home DTC as well as professional markets through practices, payers, virtual visit providers and possibly retail (one of their investors is Walgreens Boots). Release If you are attending MEDICA 2017 in Düsseldorf on 16 November, you can see Tyto Care demonstrated at the 5th Annual MEDICA App Competition.
Another all-in-one device is Las Vegas-based MedWand, which is still in pre-marketing. MedWand seems to feature clinic and ‘group’ packages as well as the individual device which includes a pulse oximeter. They received another round of undisclosed financing from Maxim Ventures, the venture arm for semi-conductor developer Maxim Integrated Products at end of September. Release.